<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545935</url>
  </required_header>
  <id_info>
    <org_study_id>MB-2007b</org_study_id>
    <nct_id>NCT00545935</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso</brief_title>
  <official_title>Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso: RCT in the Frame of the A8 Project of SFB 544</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the safety and efficacy profile of a new
      paediatric MB formulation combined with AQ or AS and compared to AS-AQ in young African
      children with uncomplicated falciparum malaria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date>October 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of observed and self-reported non-serious adverse events over the 28 days observation period</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAE) and the adequate clinical and parasitological response rate (ACPR)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early treatment failure (ETF) rate</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late clinical failure (LCF) rate at D14 and D28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late parasitological failure (LPF) rate at D14 and D28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever clearance time</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite clearance time</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in haematocrit after 2,14 and 28 days compared to baseline</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MB whole blood concentrations on D3,5 or 7 compared to concentrations after the first dose</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment>186</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>1-Methylenblue-Amodiaquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2-Methylenblue-Artesunate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3-Artesunate-Amodiaquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylenblue-Amodiaquine (MB-AQ)</intervention_name>
    <description>For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ</description>
    <arm_group_label>1-Methylenblue-Amodiaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylenblue-Artesunate (MB-AS)</intervention_name>
    <description>3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days</description>
    <arm_group_label>2-Methylenblue-Artesunate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate-Amodiaquine (AS-AQ)</intervention_name>
    <description>For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.</description>
    <arm_group_label>3-Artesunate-Amodiaquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  0.5-5 year (6-59 months) old children

          -  uncomplicated malaria caused by P. falciparum

          -  asexual parasites ≥ 2000/µ and ≤ 200000/µ

          -  axillary temperature ≥ 37.5 Celsius or a history of fever during last 24 hours

          -  Burkinabe nationality

          -  informed consent

        Exclusion Criteria:

          -  complicated or severe malaria

          -  any apparent significant disease

          -  anaemia (haematocrit &lt; 21%)

          -  treated in the same trial before

          -  modern antimalarial treatment prior to inclusion (last three days), except children
             having been treated with chloroquine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Olaf Mueller, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Recherche en Sante de Nouna</name>
      <address>
        <city>Nouna</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <last_update_submitted>February 2, 2009</last_update_submitted>
  <last_update_submitted_qc>February 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

